Medicare coverage of self-injectable products
Executive Summary
"South Carolina has the national distinction of being the only state in the U.S. where the Part B Carrier does not cover interferon for any indication...[or] the pre-operative use of epoetin alpha," Greenville, S.C. oncologist Mark O'Rourke told a recent HCFA "town hall" meeting. "The Pink Sheet" incorrectly listed products that O'Rourke considers to be "most-effectively administered by subcutaneous injection," including Amgen's Neupogen, Immunex' Leukine and Ortho's Procrit, as products not covered by the Medicare carrier (1"The Pink Sheet" July 31, p. 10)
You may also be interested in...
HCFA To Review Medicare Carrier Discretion On Self-Administered Drugs
HCFA is planning to review the amount of discretion that should be allowed to Medicare carriers on the coverage decisions for self-administerable drugs that were available through Medicare before 1997.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials